{"id":5808,"date":"2022-03-25T10:58:54","date_gmt":"2022-03-25T07:58:54","guid":{"rendered":"https:\/\/www.klimik.org.tr\/koronavirus\/?p=5808"},"modified":"2022-04-07T21:44:49","modified_gmt":"2022-04-07T18:44:49","slug":"covid-19a-karsi-guncel-bagisiklama-onerileri","status":"publish","type":"post","link":"https:\/\/www.klimik.org.tr\/koronavirus\/covid-19a-karsi-guncel-bagisiklama-onerileri\/","title":{"rendered":"COVID-19&#8217;a Kar\u015f\u0131 G\u00fcncel Ba\u011f\u0131\u015f\u0131klama \u00d6nerileri"},"content":{"rendered":"<p><a href=\"https:\/\/www.klimik.org.tr\/wp-content\/uploads\/2022\/03\/KLI\u0307MI\u0307K.Derneg\u0306inden.COVID19a.Kars\u0327i.Gu\u0308ncel.Bag\u0306is\u0327iklama.O\u0308nerileri_31.Mart_.2022-2.png\"><img decoding=\"async\" loading=\"lazy\" class=\"alignnone size-large wp-image-115824\" src=\"https:\/\/www.klimik.org.tr\/wp-content\/uploads\/2022\/03\/KLI\u0307MI\u0307K.Derneg\u0306inden.COVID19a.Kars\u0327i.Gu\u0308ncel.Bag\u0306is\u0327iklama.O\u0308nerileri_31.Mart_.2022-629x333.png\" alt=\"\" width=\"629\" height=\"333\" \/><\/a><br \/>\n<a href=\"https:\/\/www.klimik.org.tr\/wp-content\/uploads\/2022\/03\/KLI\u0307MI\u0307K.Derneg\u0306inden.COVID19a.Kars\u0327i.Gu\u0308ncel.Bag\u0306is\u0327iklama.O\u0308nerileri_31.Mart_.2022-1.pdf\"><span style=\"color: #800000;\"><strong>Tablonun PDF F<\/strong><strong>ormat\u0131 \u0130\u00e7in T\u0131klay\u0131n\u0131z<\/strong><\/span><\/a><\/p>\n<p><span style=\"color: #800000;\"><strong>1.<\/strong> <\/span>Hi\u00e7 a\u015f\u0131lanmam\u0131\u015f ki\u015filerin bir ay arayla iki doz BioNTech olduktan en erken 3 ay sonra 3. doz BioNTech a\u015f\u0131lar\u0131n\u0131 olmalar\u0131 \u00f6nerilir.<\/p>\n<p><span style=\"color: #800000;\"><strong>2.<\/strong><\/span> Hi\u00e7 a\u015f\u0131lanmam\u0131\u015f ki\u015filere mRNA a\u015f\u0131s\u0131 yap\u0131l(a)mad\u0131\u011f\u0131 durumda<strong>*<\/strong>Sinovac a\u015f\u0131s\u0131 ile \u00fc\u00e7 doz (0, 1 ve 4. aylarda) a\u015f\u0131laman\u0131n ard\u0131ndan en erken 3 ay sonra hat\u0131rlatma dozunu (yap\u0131labiliyorsa BioNTech a\u015f\u0131s\u0131 ile) olmalar\u0131 \u00f6nerilir.<\/p>\n<p><strong><span style=\"color: #800000;\">3.<\/span><\/strong> \u00c7e\u015fitli nedenlerle primer a\u015f\u0131 \u015femas\u0131 (Sinovac i\u00e7in 0,1, 4. aylarda 3 doz, BioNTech i\u00e7in bir ay arayla iki doz) yar\u0131m kalan ki\u015filerin a\u015f\u0131lamalar\u0131na kald\u0131klar\u0131 yerden devam edilmesi, hat\u0131rlatma dozlar\u0131n\u0131n primer \u015feman\u0131n tamamlanmas\u0131ndan en erken 3 ay sonra yap\u0131lmas\u0131 \u00f6nerilir.<\/p>\n<p><strong><span style=\"color: #800000;\">4.<\/span><\/strong> \u0130ki doz BioNTech a\u015f\u0131s\u0131 olmu\u015f ki\u015filerin 2. dozdan en erken 3 ay sonra hat\u0131rlatma dozunu olmalar\u0131 \u00f6nerilir.<\/p>\n<p><strong><span style=\"color: #800000;\">5.<\/span> <\/strong>\u00dc\u00e7 doz Sinovac a\u015f\u0131s\u0131 olmu\u015f ki\u015filerin son dozdan en erken 3 ay sonra hat\u0131rlatma dozlar\u0131n\u0131 (tercihen BioNTech a\u015f\u0131s\u0131 ile) olmalar\u0131 \u00f6nerilir.<\/p>\n<p><strong><span style=\"color: #800000;\">6.<\/span> <\/strong>\u0130ki doz Sinovac ard\u0131ndan bir doz BioNTech a\u015f\u0131s\u0131 olanlar\u0131n, son a\u015f\u0131dan en erken 3 ay sonra ikinci doz BioNTech a\u015f\u0131lar\u0131n\u0131 olmalar\u0131 \u00f6nerilir.<\/p>\n<p><strong><span style=\"color: #800000;\">7.<\/span> <\/strong>\u0130ki doz Sinovac ard\u0131ndan iki doz BioNTech a\u015f\u0131s\u0131 (toplam 4 doz a\u015f\u0131) olanlar i\u00e7erisinde 65 ya\u015f\u0131n \u00fczerinde olanlar, hastal\u0131k veya ilaca ba\u011fl\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k yetersizli\u011fi olanlar, altta yatan ciddi hastal\u0131\u011f\u0131 (diyaliz uygulananlar, kalp yetmezli\u011fi, ileri AC yetmezli\u011fi ve siroz) bulunanlar ve y\u00fcksek miktarda virusla kar\u015f\u0131la\u015fma riski olan ki\u015filer (sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131) hat\u0131rlatma dozunu, son a\u015f\u0131dan en erken 3 ay sonradan itibaren olabilirler. Bu gruplar d\u0131\u015f\u0131nda kalan ki\u015filerde a\u015f\u0131lar\u0131n a\u011f\u0131r hastal\u0131k ve \u00f6l\u00fcmden koruyucu etkisi devam etti\u011finden hat\u0131rlatma dozunu olmalar\u0131na \u015fimdiki bilgilere g\u00f6re gerek yoktur. \u00d6neriler, yeni veriler \u0131\u015f\u0131\u011f\u0131nda de\u011ferlendirilmelidir.<\/p>\n<p><span style=\"color: #800000;\"><strong>8.<\/strong><\/span> Daha \u00f6nce \u00fc\u00e7 doz BioNTech a\u015f\u0131s\u0131 olanlar i\u00e7erisinde 65 ya\u015f\u0131n \u00fczerinde olanlar, hastal\u0131k veya ilaca ba\u011fl\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k yetersizli\u011fi olanlar, altta yatan ciddi hastal\u0131\u011f\u0131 (diyaliz uygulananlar, kalp yetmezli\u011fi, ileri AC yetmezli\u011fi ve siroz) bulunanlar ve y\u00fcksek miktarda virusla kar\u015f\u0131la\u015fma riski olan ki\u015filer (sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131) hat\u0131rlatma dozunu, son a\u015f\u0131dan en erken 3 ay sonradan itibaren olabilirler. Bu gruplar d\u0131\u015f\u0131nda kalan ki\u015filerde a\u015f\u0131lar\u0131n a\u011f\u0131r hastal\u0131k ve \u00f6l\u00fcmden koruyucu etkisi devam etti\u011finden hat\u0131rlatma dozunu olmalar\u0131na \u015fimdiki bilgilere g\u00f6re gerek yoktur. \u00d6neriler, yeni veriler \u0131\u015f\u0131\u011f\u0131nda de\u011ferlendirilmelidir.<\/p>\n<p><strong><span style=\"color: #800000;\">9.<\/span><\/strong> \u00d6nceki varyantlarla (\u00fclkemiz i\u00e7in 1 Ocak 2022 \u00f6ncesinde) hastal\u0131k ge\u00e7irdikten sonra bir doz BioNTech olmu\u015f ki\u015filere, Omikrona ve di\u011fer varyantlara kar\u015f\u0131 uzun s\u00fcre korunduklar\u0131 i\u00e7in, \u015fimdiki bilgilere g\u00f6re ek hat\u0131rlatma dozuna gerek yoktur. Yeni veriler \u0131\u015f\u0131\u011f\u0131nda de\u011ferlendirilmelidir.<\/p>\n<p><span style=\"color: #800000;\"><strong>10.<\/strong><\/span> \u00d6nceki varyantlarla (\u00fclkemiz i\u00e7in 1 Ocak 2022 \u00f6ncesinde) hastal\u0131k ge\u00e7irdikten sonra bir doz Sinovac olanlar\u0131n, son Sinovac\u2019tan 3 ay sonra (tercihen BioNTech ile) bir hat\u0131rlatma dozu olmalar\u0131 \u00f6nerilir.<\/p>\n<p><strong><span style=\"color: #800000;\">11.<\/span><\/strong> \u0130ki doz BioNTech olmas\u0131na ra\u011fmen herhangi bir varyantla hastal\u0131k ge\u00e7irmi\u015f olan ki\u015filerin hastal\u0131ktan 6 ay sonra bir doz BioNTech a\u015f\u0131s\u0131 olmalar\u0131 \u00f6nerilir. B\u00f6ylelikle a\u015f\u0131 sonras\u0131nda Omikrona kar\u015f\u0131 en az 6 ay yeterli koruma sa\u011flanacakt\u0131r. Bu ki\u015filerin yeni bir varyant \u00e7\u0131kmad\u0131\u011f\u0131 s\u00fcrece hat\u0131rlatma dozu olmalar\u0131na \u015fimdiki bilgilere g\u00f6re gerek yoktur. Alt\u0131nc\u0131 ay\u0131n sonunda yeni veriler \u0131\u015f\u0131\u011f\u0131nda de\u011ferlendirilmelidir.<\/p>\n<p><strong><span style=\"color: #800000;\">12.<\/span><\/strong> A\u015f\u0131 \u015femas\u0131 tamamlanmadan veya hi\u00e7 a\u015f\u0131lanmadan \u00f6nceki varyantlarla (\u00fclkemiz i\u00e7in 1 Ocak 2022 \u00f6ncesinde) hastal\u0131k ge\u00e7irmi\u015f olan ki\u015filerin, hastal\u0131ktan en erken 3 ay sonra (tercihen 6. Ayda) tek doz BioNTech a\u015f\u0131s\u0131 olmalar\u0131, mRNA a\u015f\u0131s\u0131 yap\u0131l(a)mad\u0131\u011f\u0131 durumda<strong>*<\/strong>iki doz Sinovac a\u015f\u0131s\u0131 ile (0 ve 1. aylarda) a\u015f\u0131lanmalar\u0131 \u00f6nerilir.<\/p>\n<p><strong><span style=\"color: #800000;\">13.<\/span><\/strong> A\u015f\u0131 \u015femas\u0131 tamamlanmadan veya hi\u00e7 a\u015f\u0131lanmadan Omikron ile (\u00fclkemiz i\u00e7in 1 Ocak 2022 sonras\u0131nda) hastal\u0131k ge\u00e7irmi\u015f olan ki\u015filerin (Delta varyant\u0131na yeterli ba\u011f\u0131\u015f\u0131kl\u0131klar\u0131 olmayaca\u011f\u0131 i\u00e7in) hastal\u0131ktan 3 ay sonra ba\u015flamak \u00fczere 1 ay arayla iki doz BioNTech a\u015f\u0131s\u0131 olmalar\u0131 \u00f6nerilir. mRNA a\u015f\u0131s\u0131 yap\u0131l(a)mad\u0131\u011f\u0131 durumda<strong>*<\/strong>Sinovac a\u015f\u0131s\u0131 ile \u00fc\u00e7 doz (0, 1 ve 4. aylarda) a\u015f\u0131lanmalar\u0131 \u00f6nerilir.<\/p>\n<p><strong><span style=\"color: #800000;\">14.<\/span><\/strong> \u0130ki doz Sinovac ard\u0131ndan 2 doz BioNTech a\u015f\u0131s\u0131 veya 3 doz BioNTech a\u015f\u0131s\u0131 uyguland\u0131ktan sonra COVID-19 ge\u00e7irmi\u015f ki\u015filere hat\u0131rlatma dozu yap\u0131lmas\u0131na eldeki verilere g\u00f6re gerek yoktur.<\/p>\n<p><strong><span style=\"color: #800000;\">15.<\/span><\/strong> Ba\u011f\u0131\u015f\u0131kl\u0131k yetmezli\u011fi olan ki\u015filerin inaktif a\u015f\u0131 yerine mRNA a\u015f\u0131lar\u0131 ile a\u015f\u0131lanmalar\u0131 \u00f6nerilir. Bu ki\u015filerin 1 ay arayla 3 dozdan (BioNTech) olu\u015fan primer a\u015f\u0131 \u015femas\u0131n\u0131 tamamlad\u0131ktan sonra ek dozlar\u0131n say\u0131s\u0131 ve zamanlamas\u0131n\u0131n belirlenmesi i\u00e7in \u0130nfeksiyon Hastal\u0131klar\u0131 ve Klinik Mikrobiyoloji uzmanlar\u0131na ba\u015fvurmalar\u0131 \u00f6nerilir.<\/p>\n<p><img decoding=\"async\" loading=\"lazy\" class=\"alignnone wp-image-110159\" src=\"https:\/\/www.klimik.org.tr\/wp-content\/uploads\/2021\/12\/klimik-logo-png-629x234-1.png\" alt=\"\" width=\"226\" height=\"84\" \/><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tablonun PDF Format\u0131 \u0130\u00e7in T\u0131klay\u0131n\u0131z 1. Hi\u00e7 a\u015f\u0131lanmam\u0131\u015f ki\u015filerin bir ay arayla iki doz BioNTech olduktan en erken 3 ay sonra 3. doz BioNTech a\u015f\u0131lar\u0131n\u0131 olmalar\u0131 \u00f6nerilir. 2. Hi\u00e7 a\u015f\u0131lanmam\u0131\u015f ki\u015filere mRNA a\u015f\u0131s\u0131 yap\u0131l(a)mad\u0131\u011f\u0131 durumda*Sinovac a\u015f\u0131s\u0131 ile \u00fc\u00e7 doz (0, 1 ve 4. aylarda) a\u015f\u0131laman\u0131n ard\u0131ndan en erken 3 ay sonra hat\u0131rlatma dozunu (yap\u0131labiliyorsa BioNTech a\u015f\u0131s\u0131 ile) olmalar\u0131 \u00f6nerilir. 3. \u00c7e\u015fitli nedenlerle primer a\u015f\u0131 \u015femas\u0131 (Sinovac i\u00e7in 0,1, 4. aylarda 3 doz, BioNTech i\u00e7in bir ay arayla iki doz) yar\u0131m kalan ki\u015filerin a\u015f\u0131lamalar\u0131na kald\u0131klar\u0131 yerden devam edilmesi, hat\u0131rlatma dozlar\u0131n\u0131n primer \u015feman\u0131n tamamlanmas\u0131ndan en erken 3 ay sonra yap\u0131lmas\u0131 \u00f6nerilir. 4. [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":5810,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5808"}],"collection":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/comments?post=5808"}],"version-history":[{"count":9,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5808\/revisions"}],"predecessor-version":[{"id":5839,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5808\/revisions\/5839"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media\/5810"}],"wp:attachment":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media?parent=5808"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/categories?post=5808"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/tags?post=5808"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}